Impact of the Development of Pediatric Palliative Care

NCT05660499 | Unknown

• 1 other identifier: 8137
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Despite medical advances, cancer remains the leading cause of death by disease in children. Brain tumors are the second most common cause of cancer in children after leukemia, representing 25% of pediatric cancers. The overall survival rate is about 50% with extremes ranging from less than 5% to more than 90% depending on the histological type of brain tumor. The end of life of children with a brain tumor is marked by the possibility of discomfort symptoms, painful or not, and by a progressive neurological deterioration, which makes the management of these children complex for both families and health professionals. Over the last decade, the concept of palliative care has been increasingly integrated into pediatric onco-hematology services with the primary objective of better symptom control in a global approach to the child and his or her family in order to aim at a better quality of life.

Conditions

Primary Brain Tumor

Keywords

Primary Brain Tumor; Pediatric Palliative Care

Outcome Measures

Primary Outcomes (1)

• Presence of symptoms of physical or psychological discomfort in the last 4 months of life

  up to the last 4 months of life

Eligibility Criteria

• Age: 1 Year - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

\- Patient less than 17 years of age suffering from a primary brain tumor

You may qualify if:

• Patient less than 17 years of age
• Suffering from a primary brain tumor
• Died during the period 2009-2010 or during the period 2019-2020
• Follow-up in one of the Pediatric Oncology departments participating in the study (Strasbourg, Besançon, Dijon, Nancy and Reims)
• Absence of refusal expressed in the medical file by the parents or the holder(s) of parental authority concerning the reuse of the child's personal data for research purposes.

You may not qualify if:

• Refusal expressed in the medical file by the parents or the holder(s) of parental authority concerning the reuse of the child's personal data for research purposes
• Patient with a brain tumor secondary to another cancer

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de soins Palliatifs - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Central Study Contacts

Nadine COJEAN, MD

CONTACT

33 6 21 11 16 01; nadine.cojean@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 13, 2022
• First Posted: December 21, 2022
• Study Start: February 15, 2021
• Primary Completion: December 1, 2023
• Study Completion: December 31, 2023
• Last Updated: December 14, 2023

Record last verified: 2023-12

Locations

FR (1)